Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15181954 | 0.85 | SIRT2 (0.31) | MEN1CYP2C9KMT2A | |
| SCHEMBL27070172 | 0.84 | KDM4E (0.34) | KDM4ELMNACYP2C19TSHRNPSR1 | |
| SCHEMBL13911598 | 0.82 | — | — | |
| SCHEMBL9356226 | 0.82 | HSD17B10 (0.34) | — | |
| SCHEMBL9873984 | 0.80 | ALDH1A1 (0.38) | MEN1CYP2C9KMT2ALMNACYP2C19 | |
| SCHEMBL21315250 | 0.80 | PRMT1 (0.31) | — | |
| SCHEMBL2223307 | 0.79 | MEN1 (0.32) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL7750061 | 0.76 | KDM4E (0.46) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL8807934 | 0.75 | TP53 (0.30) | CYP2C19 | |
| SCHEMBL9356126 | 0.75 | HSD17B10 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692071-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS | TOKUYAMA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| EP-4692072-A1 | PHOTOCHROMIC COMPOUND, PROPARGYL ALCOHOL COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND SPECTACLES | TOKUYAMA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025041625-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | 株式会社トクヤマ | 2025-02-27 | — | — | WO | disclosed |
| WO-2025041624-A1 | PHOTOCHROMIC COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | 株式会社トクヤマ | 2025-02-27 | — | — | WO | disclosed |
| WO-2025028365-A1 | PHOTOCHROMIC COMPOUND, PHENOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS | 株式会社トクヤマ | 2025-02-06 | — | — | WO | disclosed |
| WO-2024202086-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS | 株式会社トクヤマ | 2024-10-03 | — | — | WO | disclosed |
| WO-2024202087-A1 | PHOTOCHROMIC COMPOUND, PROPARGYL ALCOHOL COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND SPECTACLES | 株式会社トクヤマ | 2024-10-03 | — | — | WO | disclosed |
| CN-116981742-A | Antifouling coating composition | 日东化成株式会社 | 2023-10-31 | — | — | CN | disclosed |
| EP-3704089-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3018115-B1 | NOVEL PHENYL NAPTHOL DERIVATIVE | TOKUYAMA CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2006-12-14 | — | — | US | disclosed |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| WO-2006100631-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
| EP-1698620-A1 | BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-6384065-B1 | CONTROL THE FUNCTIONS OF PROTEINS SUCH AS ENZYMES AND RECEPTOR FORTREATING INFLAMMATORY DISEASES SUCH AS RHEUMATOID ARTHRITIS, | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1076056-A1 | NOVEL SPIRO COMPOUNDS OR SALTS THEREOF AND PREVENTIVES/REMEDIES FOR AUTOIMMUNE DISEASES AND AP-1 INHIBITORS CONTAINING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-02-14 | — | — | EP | disclosed |
| EP-0310321-B1 | Immunomodulatory azaspiranes | SMITHKLINE BEECHAM CORP (US) | 1994-11-30 | — | — | EP | disclosed |
| WO-1989002889-A1 | IMMUNOMODULATORY AZASPIRANES | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-06 | — | — | WO | disclosed |
| EP-0310321-A2 | Immunomodulatory azaspiranes | SMITHKLINE BEECHAM CORPORATION (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | CCR10, H1-10, CXCL10 | MEN1 2708/4885CYP2C9 1796/4885KMT2A 3644/4885 |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | CCR10, HRH3, HRH2 | MEN1 2969/4885CYP2C9 998/4885KMT2A 2951/4885 |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | HRH3, CCR10, HRH1 | MEN1 2159/4885CYP2C9 1481/4885KMT2A 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.